UCB agreed to acquire Neurona Therapeutics in a cash-and-milestones transaction valued at $1.15 billion to expand its epilepsy pipeline. The deal structure includes a $650 million upfront payment, with up to $500 million in additional milestone payments tied to development and commercial milestones. At the center of the acquisition is Neurona’s NRTX-1001, a pluripotent stem cell–derived therapy engineered to produce GABA for seizure reduction. UCB said it expects the one-time approach to offer durable benefit, contrasting with today’s anti-seizure regimens that are typically taken repeatedly. Regulatory designations support the asset’s accelerated development trajectory. NRTX-1001 received RMAT designation from the FDA in 2024 and EMA PRIME designation following that, positioning the program for earlier and more iterative regulatory engagement. For Neurona, the transaction follows investor focus on regenerative neurology and the ability to convert initial clinical signals into scalable development. For UCB, the move adds an advanced clinical-stage, potentially disease-modifying platform to complement its existing anti-epilepsy portfolio.